August 16, 2011:
JERRY TREPPEL~~THE MAN WITH THE PLAN!!!
Medi Amari - Shareholder - Analyst
Okay, and about the ab-user -- because I guess FDA's pushing pharma industry for ab-user use of the drugs and especially these Oxy products. What do you think that's going to be in the future, next 10 years of ELI216, if approved?
Jerry Treppel - Elite Pharmaceuticals Inc - Chairman, CEO
Well, I can put forth a personal opinion. As part of the approval -- when they approve these abuse resistant products, they asked all of the companies basically to do a follow-up. And, so, they can get a handle on does the abuse resistant technology actually lead to less abuse of the products.
My guess is yes. And, I think when the agency has that data in hand, they are basically going to mandate that opioids be in an abuse resistant formulation.
January 9, 2013
FDA issues draft guidance on abuse-deterrent opioids